Clinical trials: GLP-1
Type 2 Diabetes, Obesity
Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery
Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems. Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2).
- Trial name
- GIP-PET (NCT01880827)
- Testing
- Roux-en-Y, GIP-infusion, GLP-1
- Where
- Finland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Healthy
Glycaemic Response, Insulinaemic Response, GLP-1 and GIP Testing of Food Product Lines
The aim of this study was to compare the glycaemic response, insulinaemic response, GIP response and GLP-1 response to glucose, 25 g Nutralys S85 Plus and 50 g Nutralys S85 Plus using a single-blind, randomised, repeat measure…
- Trial name
- NCT04610203
- Testing
- 25 g Nutralys Pea Protein, 50 g Nutralys S85 Plus., 50 g Glucose
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Oxford Brookes University
Healthy
GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow
to investigate the effect of the human incretin hormone GLP-1 on mesenteric blood flow and cardiac parameters
- Trial name
- NCT01988545
- Testing
- 1,5 nmol/kg,GLP-1 sc injection, 1,5 nmol/kg GLP-1 9-36amide, sc injection, Exendin-4 ;10 ug,sc injection
- Where
- Denmark
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Zealand University Hospital
Laxity; Skin
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator…
- Trial name
- NCT07558603
- Testing
- On GLP1 plus HRT, On GLP1 Only
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
Healthy
Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients
This pilot study is aimed at assessing the acute effect of several combinations of lipids differing in their fatty acid composition on glucagon-like-peptide (GLP)-2 and GLP-1 secretion in healthy subjects.
- Trial name
- NCT01727583
- Testing
- meal intake
- Where
- Switzerland
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity, Overweight
The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior
The goal of this study is to explore whether of GLP-1 receptor agonist use is associated with differences in taste, smell, food preferences, appetite, food cravings, and responses to food cues in adults.
- Conditions
- Obesity, Overweight, Taste Perception, Olfaction
- Trial name
- NCT07611201
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Purdue University
Heart Disease
Effect of GLP-1 on Postprandial Lipid Metabolism
Individuals with obesity have an increased risk for heart disease and diabetes. There are current drugs on the market that target the hormone, Glucagon like peptide-1 (GLP-1) to treat diabetes.
- Trial name
- NCT01760772
- Testing
- Exendin-9, GLP-1, saline
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- David Dalessio
Healthy Adults
Safety and Tolerance of a Novel Three-Strain Probiotic in Healthy Adults
This Phase I \& II study evaluates the safety and tolerability of 8 weeks of daily supplementation with high-dose versus standard-dose of a novel three-strain probiotic.
- Trial name
- NCT07566884
- Testing
- Three-Strain Probiotic
- Where
- Ireland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pendulum Therapeutics
Type 2 Diabetes Mellitus
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus
This study is designed to evaluate the safety and tolerability of a range of single oral doses of LGD-6972 in healthy subjects. Additionally, the study will characterize the Pharmacokinetic profile in healthy subjects under fed…
- Trial name
- NCT01919684
- Testing
- LGD-6972
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Ligand Pharmaceuticals
Short Bowel Syndrome
Plasma Determination of Glucagon-like Peptide 2 as a Predictor of Recovery in Adults With Acute Intestinal Failure
The purpose of this study is to investigate the theory that the plasma level of Glucagon like peptide 2 (GLP-2) in patients with intestinal failure can predict their clinical recovery.
- Trial name
- NCT00180648
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
Diabetic lower extremity arterial disease ( DLEAD ), is a common complication of type 2 diabetes. However, DLEAD remains less studied than other diabetic vascular complications; and only few randomised controlled trials (RCTs)…
- Trial name
- NCT04146155
- Testing
- Liraglutide+standard-of-care treatment, standard-of-care treatment
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Adult Growth Hormone Deficiency, Hypothalamic-pituitary Disorders
The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis
The purpose of this study is to find out if the Glucagon Stimulation Test (GST) is a reliable alternative to the Insulin Tolerance Test (ITT) for diagnosis of Growth Hormone Deficiency (GHD) and adrenal insufficiency.
- Trial name
- GST (NCT01282164)
- Testing
- Glucagon stimulation test and insulin tolerance test
- Where
- 4 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Obesity, Overweight
A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight
The primary objective of this study is to evaluate the effect of a meal and evening dosing on the pharmacokinetics (PK) of KAI 7535 in healthy participants living with obesity or overweight.
- Trial name
- NCT07294898
- Testing
- KAI-7535
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Kailera
Obesity, Smoking Cessation
Gut Hormones in Obesity, Nicotine and Alcohol Dependence
The "Gut Hormones in Addiction" study is a proof-of-concept experimental medicine human study to answer the following questions: 1.
- Conditions
- Obesity, Smoking Cessation, Alcoholism
- Trial name
- GHADD (NCT02690987)
- Testing
- Exenatide, Desacyl ghrelin, Saline
- Where
- United Kingdom
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Weight Loss, NASH
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735
This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and…
- Trial name
- NCT05203237
- Testing
- VK2735, VK2735 Drug
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Viking Therapeutics, Inc.
Obesity
Incretin Effect in People With Impaired Fasting Glucose
Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to abnormal EGP and insulin secretion in people…
- Trial name
- 1651 (NCT00795275)
- Testing
- Sitagliptin Phosphate
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Lack of Satiety
Fibersol-2 Clinical Trials Related to Appetite
Emerging research suggests fiber, particularly digestion-resistant maltodextrins such as Fibersol-2, may impact satiety, by decreasing hunger, prolonging satiation, and/or increasing satiety signals from the gut.
- Trial name
- NCT01305291
- Testing
- digestion-resistant maltodextrin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Iowa State University
Type 1 Diabetes Mellitus
Real-time Adaptation to Changes in Insulin Sensitivity
The purpose of this research study is to test an automated blood glucose control system that includes a new component designed to adapt to stress.
- Trial name
- NCT01261052
- Testing
- The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm, The Adaptive Proportional Derivative Algorithm
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Legacy Health System
Insulin Resistance, Glucose Intolerance
Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect
The purpose of this study is to examine whether there is a causal relationship between insulin resistance and/or glucose intolerance in the development of a defect incretin effect.
- Trial name
- NCT00784745
- Testing
- Dexamethasone
- Where
- Denmark
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes
Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes
In patients with type 2 diabetes, the incretin effect is markedly reduced contributing to the relative insulin deficiency that characterizes these patients.
- Trial name
- NCT02669524
- Testing
- LY2409021, OGTT, IIGI
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen